Oncology

Adimab's stellar 2025 reveals its crucial role as the hidden tech platform driving drug discovery for giants like Lilly and Regeneron.

NYU Langone and tech firm Tempus are launching a new protocol using serial DNA sequencing and AI to create hyper-personalized cancer treatments.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

AbbVie inks a massive deal for a novel bispecific antibody, aiming to combine it with ADCs and enter the high-stakes race for solid tumor therapies.

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

Cytek Biosciences reports preliminary 2025 revenue of $201M, beating estimates with a major Q4 growth surge ahead of its key J.P. Morgan presentation.

New clinical data suggests a more convenient option for cancer patients, potentially eliminating a return trip to the clinic for a key supportive care drug.

A novel drug that glues cancer proteins to the cellular trash system has entered human trials, offering new hope for rare diseases like Ewing sarcoma.

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

The Oncology Institute promotes new CIO and CPO, signaling a strategic push into AI-driven care and robust talent management to dominate the market.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

A new AI-designed vaccine, TG4050, has prevented relapse in all head and neck cancer patients in a key trial, signaling a breakthrough in personalized medicine.

A major pharma giant is betting on artificial intelligence to accelerate cancer drug discovery, a move that could reshape the future of oncology treatment.

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.

With a new CEO from Illumina and Exact Sciences, Quanterix signals a strategic shift from tech development to aggressive market and clinical expansion.

The 2025-2030 Dietary Guidelines praise eggs as a top protein, but experts question the new, broader focus on animal products and increased protein intake.